Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial.
Evans TG, Bussey L, Eagling-Vose E, Rutkowski K, Ellis C, Argent C, Griffin P, Kim J, Thackwray S, Shakib S, Doughty J, Gillies J, Wu J, Druce J, Pryor M, Gilbert S. Evans TG, et al. Among authors: eagling vose e. Lancet Infect Dis. 2022 Jun;22(6):857-866. doi: 10.1016/S1473-3099(21)00702-7. Epub 2022 Mar 16. Lancet Infect Dis. 2022. PMID: 35305317 Clinical Trial.
Assessment of CD8+ T-cell mediated immunity in an influenza A(H3N2) human challenge model in Belgium: a single centre, randomised, double-blind phase 2 study.
Evans TG, Castellino F, Kowalik Dobczyk M, Tucker G, Walley AM, Van Leuven K, Klein J, Rutkowski K, Ellis C, Eagling-Vose E, Treanor J, van Baalen C, Filkov E, Laurent C, Thacker J, Asher J, Donabedian A. Evans TG, et al. Among authors: eagling vose e. Lancet Microbe. 2024 May 7:S2666-5247(24)00024-7. doi: 10.1016/S2666-5247(24)00024-7. Online ahead of print. Lancet Microbe. 2024. PMID: 38729196 Free article.
Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS).
Butler C, Ellis C, Folegatti PM, Swayze H, Allen J, Bussey L, Bellamy D, Lawrie A, Eagling-Vose E, Yu LM, Shanyinde M, Mair C, Flaxman A, Ewer K, Gilbert S, Evans TG, On Behalf Of The Invictus Investigators. Butler C, et al. Among authors: eagling vose e. Vaccines (Basel). 2021 Aug 3;9(8):851. doi: 10.3390/vaccines9080851. Vaccines (Basel). 2021. PMID: 34451976 Free PMC article.